secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2024-12-09T23:59:59+00:00
Accession:  0001193125-24-272936
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta reports positive Phase 2 data for zelicapavir in pediatric RSV: 1.4 log viral load drop at Day 5
--------------------------------------------------------------------------------

- Part 2 primary endpoint: 1.4 log viral load decline at Day 5 vs placebo (n=34 zelicapavir, n=10 placebo).
- Prespecified early-treatment subset (within 3 days of symptom onset): 1.2 log decline at Day 5 vs placebo.
- 96 patients (70 zelicapavir, 26 placebo) aged 28 days to 36 months; no AEs leading to discontinuation.
- Dose selected: 5 mg/kg for ≥28 days to <12 months; 7.5 mg/kg for ≥12 to ≤36 months.
- Symptom tool RESOLVE-P showed trend toward reduction but data available for only 15 patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000119312524272936/0001193125-24-272936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000119312524272936/d706648d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-272936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer